E-viri
PDF
Recenzirano
Odprti dostop
-
von Minckwitz, Gunter; Huang, Chiun-Sheng; Mano, Max S; Loibl, Sibylle; Mamounas, Eleftherios P; Untch, Michael; Wolmark, Norman; Rastogi, Priya; Schneeweiss, Andreas; Redondo, Andres; Fischer, Hans H; Jacot, William; Conlin, Alison K; Arce-Salinas, Claudia; Wapnir, Irene L; Jackisch, Christian; DiGiovanna, Michael P; Fasching, Peter A; Crown, John P; Wülfing, Pia; Shao, Zhimin; Rota Caremoli, Elena; Wu, Haiyan; Lam, Lisa H; Tesarowski, David; Smitt, Melanie; Douthwaite, Hannah; Singel, Stina M; Geyer, Charles E
New England journal of medicine/The New England journal of medicine, 02/2019, Letnik: 380, Številka: 7Journal Article
Residual cancer after induction therapy for HER2-positive breast cancer is associated with a worse prognosis than no residual cancer. In a randomized trial, trastuzumab emtansine was superior to trastuzumab with respect to invasive disease–free survival.
